- 80% of Black or African American people
- 60% of Asian or Pacific Islander people
- 50% of Hispanic or Latino people
- 40% of American Indian or Alaskan Native people
- 20% of White people
People who don’t have a fully matched donor can get a mismatched donor. But, mismatched BMTs are more likely to cause a serious problem called graft-versus-host disease (GVHD). GVHD can affect skin, lungs and other organs.
A new study shows that giving a certain medicine, cyclophosphamide, after mismatched BMT helps reduce GVHD.
Making mismatched BMT safer will help everyone who needs BMT, especially people of color, whose racial and ethnic backgrounds are under-represented in the donor registry.
This study involved 80 people in the U.S. who were 15 to 71 years old. All had a blood cancer: acute or chronic leukemia, myelodysplastic syndrome, or lymphoma. None of the people had a fully matched donor. About half the people in the study were people of color, and more than a third used a donor with more than one mismatch.
A year after mismatched BMT, 76% of people were alive, which are good results for such serious cancers.